Cagent Vascular
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
150 Strafford Ave Ste 315, Wayne, Pennsy...Phone Number
(610) 688-2006Website
www.cagentvascular.comRevenue
$8 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Cagent Vascular
Cagent Vascular Inc. specializes in the development of innovative angioplasty balloons utilizing their proprietary Serration Technology aimed at enhancing treatments for cardiovascular diseases. The company's flagship product, the Serranator, is designed to optimize lumen gain and mitigate complications during procedures. Targeted at healthcare providers and medical professionals, Cagent Vascular seeks to set a new standard of care in the field of vascular interventions. Their dedicated approach emphasizes improving patient outcomes and overall quality of life in those affected by cardiovascular conditions.Explore more
Cagent Vascular Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cagent Vascular your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cagent Vascular had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Cagent Vascular, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Cagent Vascular has new funding data
Congratulate Masked Content for being promoted to Masked Content at Cagent Vascular
Check if Cagent Vascular has recently received funding, and reach out quickly before it becomes old news!
Check out if Cagent Vascular is spiking on competitors!
Product Launch: Get notified when Cagent Vascular launches new products
Earning: See what the market has to say on Cagent Vascular recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Cagent Vascular
Compare insights from companies similar to Cagent Vascular, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cagent Vascular
$8M
11-50
Private
$107M
2014
CL
Corey LatanisionSenior VP, Marketing & International Sales
<$5M
51-200
Private
<$5M
2013
MB
Michelle BaDirector, Ancillary Services Cardiac & Vascular Diagnostic Medical Sonographer
Company Profile Activity
Activity Insights
Cagent Vascular is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cagent Vascular is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cagent Vascular.
Cagent Vascular financials insights
Gather financial insights about Cagent Vascular, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series B
$11.9M
2020
Debt
$150K
2021
Private Equity
$9M
2024
Series C
$30M
2025
Private Equity
$15M
2026
Series D
$41M
Cagent Vascular Tech Stack
A closer look at the technologies used by Cagent Vascular
Most Recent Scoops
Pain Point
Project
, according to a mid-level source in content & experience, is planning to remediate challenges related to competitive intelligence. The organization will focus on sales knowledge and training initiative to address these challenges.
Pain Point, Business Intelligence, Analytics & Insights, Training, Sales
Project
, according to a mid-level source in content & experience, is planning to begin initiatives related to marketing resource management (MRM) within three to six months.
Workforce Management, Marketing Operations
Project
, according to a mid-level source in content & experience, is planning to begin initiatives related to account-based marketing (ABM) within three to six months. The organization is working to identify accounts that require nurturing to support these efforts.
Relationship Marketing, Marketing Strategy
Pain Point
Project
, according to a mid-level source in content & experience, is planning to remediate challenges related to improving sales and marketing alignment. Cagent Vascular is planning to update workflow.
Pain Point, Sales
Event
Project
Events, Collaboration/Web Apps, Video
Cagent Vascular News & Media
Cagent Vascular and 3comma Medical Announce Strategic Partnership to Expand International Distribution of Serranator Product Family in EU and MENA Regions
WAYNE, Pa.--(BUSINESS WIRE)-- #CLI--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced its strategic partnership with 3comma Medical GmbH, a commercial services firm that specializes in bringing innovative medical device products to international markets. Under this collaboration, 3comma will serve as the exclusive international (OUS) distributor in EU and MENA regions for Cagent Vascular, leveraging its extenCagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
WAYNE, Penn.--(BUSINESS WIRE)-- #CLI--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company’s commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning ofCagent Vascular Receives $15M in Growth Capital From Trinity Capital
Cagent Vascular, a Wayne, PA-based developer of serration technology for vessel dilation in endovascular interventions, received $15M in growth capital from Trinity Capital (NASDAQ: TRIN). This capital augmented $45M of equity financing led by US Venture Partners in 2024. The company intends to use the funds to expand operations and its business reach. Led by CEO Brian Walsh, […] The post Cagent Vascular Receives $15M in Growth Capital From Trinity Capital appeared first on FinSMEs.Trinity Capital Inc. Provides $15 Million in Growth Capital to Cagent Vascular Inc.
PHOENIX, Feb. 20, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ: TRIN) ("Trinity Capital"), a leading alternative asset manager, today announced the commitment of $15 million in growth capital to Cagent Vascular Inc., a leading developer of serration technology for vessel dilation in...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cagent Vascular
Sign Up For FreeTo access detailed company insights
Cagent Vascular Inc. specializes in the development of innovative angioplasty balloons utilizing their proprietary Serration Technology aimed at enhancing treatments for cardiovascular diseases. The company's flagship product, the Serranator, is designed to optimize lumen gain and mitigate complications during procedures. Targeted at healthcare pro... Read More
